active PI3K pathway, and have direct effect on prognosis of breast cancer. Although many small molecules are used in clinic to target the PI3K pathway, only minority of breast cancer patients respond to these drugs. This study identified the role of a deubiquitinating enzyme, USP10 in the regulation of PI3K pathway in breast cancer. Methods: A genome wide RNAi screen targeting all known deubiquitinating enzymes was performed and level of phospho-AKT was assessed by western blotting. Significant hits of the screen were validated and mechanism of action in PTEN-mediated regulation of PI3K pathway and resistance to PI3K inhibitors in breast cancer has been investigated. Results: We identified USP10 as a critical regulator of PI3K pathway. MAGI1 has been recently identified as PTEN interacting protein, and along with MEK1 functions to promote PTEN recruitment to the plasma membrane. We found USP10 as a part of complex between MEK1, MAGI1 and PTEN. Functionally, we demonstrated that USP10 stabilizes ITCH which is an E3 ligase for MEK1 resulting in degradation of MEK1 and decreased PTEN plasma membrane localization. We showed that downregulation of USP10 decreases activation of AKT, and results in decreased colony forming ability of breast cancer cells. Furthermore, expression analysis of USP10 revealed significantly higher levels of USP10 in breast cancer patients and its expression was correlated with the tumor progression and poorer overall survival in the breast cancer patients. Interestingly, we showed the upregulation of USP10 protein level in PI3K inhibitor resistant breast cancer cells as compared to their parental control and further depletion of USP10 resensitized these cells to PI3K inhibitors. In addition, positive correlation between USP10 and PTEN protein levels was observed in the PDX model of breast cancer patients who progressed after receiving PI3K inhibitor. Conclusions: Overall, our results identify overexpression of USP10 as a potential mechanism for loss of PTEN functionality and PI3K pathway in breast cancer patients, and its possible involvement in resistance to PI3K inhibitors. Legal entity responsible for the study: National University of Singapore Funding: National University of Singapore Disclosure: All authors have declared no conflicts of interest. Background: A phase I clinical trial of Pevonedistat (MLN4924), a NEDD8-activating enzyme inhibitor, in AML and MDS showed modest clinical activity as a single agent. A phase II trial with Pevonedistat plus Azacytidine versus single-agent Aza is ongoing. As yet, there is no data regarding activity or dysfunction of the NEDDylation pathway in MDS. We examined NEDDylation pathway protein expression and its prognostic relevance in MDS. Methods: On a tissue microarray (TMA) with bone marrow biopsies from 119 MDS patients, 40 AML pts, and 11 normal controls, we established immunohistochemistry (IHC) for NEDD8, NAE1 and UBE2M. Semi-quantitative analysis was done according to Remmele-Stegner immunoreactive score (IRS) (0 to 12 points). Clinical follow-up was available for 116 pts. Results: Of 96 evaluable MDS pts, 46 (39.7%) showed an abnormal karyotype. Ten patients who received disease-modifying treatment prior to biopsy were excluded from survival analysis. On IHC, 100% of 40 AMLs and 11 normal controls were clearly positive (IRS>4) for all three NEDDylation pathway proteins. MDS patients showed a different pattern. While NEDD 8 was positive in the majority (60.6%), NAE1 and UBE2M were expressed in only 30.8% and 29.4%, respectively. For each protein, expression was not correlated with MDS type (WHO 2016), IPSS-R risk group, overall survival or AML transformation. Patients with strong expression of all three proteins survived longer (51 vs. 26 months), but the difference did not reach statistical significance (p ¼ 0.10). Low expression of NAE1 and UBE2M significantly correlated with the presence of karyotype anomalies (p ¼ 0.01 and p ¼ 0.02, respectively). Conclusions: In contrast to AML, expression of NEDD8 conjugation pathway proteins was low in a substantial proportion of MDS patients. The significant association between low or absent expression of NAE1 and UBE2M, and the presence of karyotype anomalies, suggests that low NEDDylation pathway activity may contribute to chromosomal instability. Nevertheless, since NEDD8 increases DNMT3b-dependent DNA methylation, NEDDylation pathway inhibition may be useful to augment treatment with hypomethylating drugs or counteract resistance to this therapy. Background: NOX66 is under development to enhance standard chemotherapy and radiotherapy. The target of idronoxil (the active constituent of NOX66), ENOX2, is an optimal candidate anti-cancer drug due to its tumour-cell specific expression. Inhibition of ENOX2 leads to a disruption of the TMEP, causing a cascade of intracellular actions leading to direct cytotoxicity and inhibition of DNA repair pathways. Three Phase 1 studies are underway to observe safety and efficacy signals -investigating multiple dose levels of NOX66 as monotherapy and in combination with carboplatin, palliative dose EBRT, and 
